Researchers say the data further support the use of an FFR-first strategy in treating intermediate coronary lesions.

The lower rate of net adverse clinical events was driven by less bleeding in those on 1 month of prasugrel-based DAPT.

Our most-read articles explore “occlusion MI” versus STEMI, TAVI in asymptomatic AS, and highlights from recent conferences.